Use: Labeled indications
- COMBIVENT RESPIMAT is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (COPD)…
Full indications and usage US FDA label
1 INDICATIONS AND USAGE COMBIVENT RESPIMAT is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. COMBIVENT RESPIMAT Inhalation Spray is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 ‑adrenergic agonist) indicated for: Patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator (1)
Contraindications
4 CONTRAINDICATIONS COMBIVENT RESPIMAT is contraindicated in the following conditions [see Warnings and Precautions (5.6)]: Hypersensitivity to any of the ingredients in COMBIVENT RESPIMAT Hypersensitivity to atropine or any of its derivatives Hypersensitivity to any of the ingredients in COMBIVENT RESPIMAT (4) Hypersensitivity to atropine or any of its derivatives (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION The recommended dosage of COMBIVENT RESPIMAT is one inhalation four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed six in 24 hours. Prior to first use, the COMBIVENT RESPIMAT cartridge is inserted into the COMBIVENT RESPIMAT inhaler and the unit is primed.
When using the unit for the first time, patients are to actuate the inhaler toward the ground until an aerosol cloud is visible and then repeat the process three more times. The unit is then considered primed and ready for use. If not used for more than 3 days, patients are to actuate the inhaler once to prepare the inhaler for use.
If not used for more than 21 days, patients are to actuate the inhaler until an aerosol cloud is visible and then repeat the process three more times to prepare the inhaler for use [see Patient Counseling Information (17)]. Safety and efficacy of additional doses of COMBIVENT RESPIMAT beyond six inhalations/24 hours have not been studied.
Also, safety and efficacy of extra doses of ipratropium or albuterol in addition to the recommended doses of COMBIVENT RESPIMAT have not been studied. For oral inhalation only One inhalation four times a day, not to exceed six inhalations in 24 hours (2)
Dosing: Altered kidney function
Renal Impairment The pharmacokinetics of COMBIVENT RESPIMAT or ipratropium bromide has not been studied in patients with hepatic or renal insufficiency.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of COMBIVENT RESPIMAT in pediatric patients have not been established. COMBIVENT RESPIMAT is indicated for use in patients with COPD on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. This disease does not normally occur in children.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In the 12-week trial in COPD, 48% of COMBIVENT RESPIMAT clinical trial patients were 65 years of age or over. In general, there were no marked differences between the proportion of patients with adverse reactions for the COMBIVENT RESPIMAT and CFC-propelled COMBIVENT Inhalation Aerosol treated patients.
Cardiac and lower respiratory disorders occurred less frequently in the patients under the age of 65 and were balanced across treatment groups. No overall differences in effectiveness were observed among treatment groups. Based on available data, no adjustment of COMBIVENT RESPIMAT dosage in geriatric patients is warranted.
Dosage forms
Philippines
- Solution for inhalation: 2.5 mg + 500 mcg, 2.5 mg/500 mcg, 2.5 mg/500 mcg per 2.5 mL, 500 mcg/2.5 mg, 500 mcg/2.5 mg per 2.5 mL, 500 mcg/2.5 mg/2.5 mL
- Solution for nebulization: 2.5 mg/500 mcg per 2.5 mL, 500 mcg/2.5 mg, 500 mcg/2.5 mg per 2.5 mL
- Per ml solution for inhalation: 1 mg/200 mcg, 200 mcg/1 mg
- Per actuation metered dose inhaler: 20 mcg/100 mcg, 100 mcg/20 mcg
- ) solution for inhalation: 1 mg/200 mcg per mL (2.5 mg/500 mcg per 2.5 mL, 200 mcg/1 mg per mL (500 mcg/2.5 mg per 2.5 mL
- Nebulizer solution: 2.5 mg/500 mcg per 2.5 mL
- Metered dose inhaler: 100 mcg/20 mcg
- Per actuation suspension metered dose inhaler: 20 mcg/100 mcg
- Solution for inhalation solution for inhalation: 500 mcg/2.5 mg per 2.5 mL
Registered products in the Philippines
105 products registered with the Food and Drug Administration (FDA) Philippines list Ipratropium + Salbutamol as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Salbutamol (as Sulfate) + lpratropium Bromide (1 product). Products registered under these spellings are included in the table and marked.
All registered products105
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AerosyncSalbutamol (as sulfate) + Ipratropium Bromide | 2.5 mg / 500 mcg per 2.5 mL Solution for InhalationLDPE ampoule x 5 mL (2.5 mL net content) by strips of 7’s (Box of 35’s) | Rx | Ahlcon Parenterals (India) LimitedIndia | Premier Pharmaceuticals Marketing Corp.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13901-02 | May 15, 2028 | |
AerosyncSalbutamol (as sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7’s (Box of 35’s) | Rx | Ahlcon Parenterals (India) LimitedIndia | Premier Pharmaceuticals Marketing Corp.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13048-11 | Nov 24, 2027 | |
AetropsalSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg/ 500 mcg per 2.5 mL Solution for Inhalation2.5mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's) | Rx | AHLCON PARENTERALS (INDIA) LIMITEDIndia | DYNASTY PHARMACEUTICALSImporter: AMBICARE PHARMACEUTICALS INC.Trader: HIGHKON PHARMA | DRP-13048-03 | Nov 24, 2027 | |
AetropsalIpratropium Bromide + Salbutamol (as Sulfate) | 200 mcg/1 mg per mL Solution for Inhalation2.5mL Translucent LDPE Ampoule (5 Ampoules Enclosed in Aluminum Foil Pouch) (Box of 5's and 20's) | Rx | Geofman PharmaceuticalsPakistan | Dynasty PharmaceuticalsImporter: Sahar International Trading, Inc. | DRP-5276-04 | Jul 24, 2027 | |
Airzol PlusIpratropium bromide + Salbutamol (as sulfate) | 500 mcg/2.5 mg per 2.5 mL Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules, Box of 25’s) and (Box of 6 ampoule strips x 5 ampoules, Box of 30's) Not Applicable | Rx | Legency Remedies Pvt. Ltd.India | Roymed PharmaceuticalImporter: Suhitas Pharmaceuticals Inc. | DRP-13475-11 | Feb 27, 2028 | |
Alventil PlusSalbutamol (as sulfate) + Ipratropium bromide | 1 mg/200 mcg per mL (2.5 mg/500 mcg per 2.5 mL) Solution for InhalationLDPE plastic ampoule x 2.5 mL (net content) in aluminum pouch x 5's (Box of 30's) | Rx | Legency Remedies Pvt. Ltd.India | Endure Medical, Inc. | DRP-16038 | Oct 18, 2029 | |
AlveoventSalbutamol (as sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE ampoule x 5 mL (2.5 mL net content) by strips of 7’s (Box of 35’s) | Rx | Ahlcon Parenterals (India) LimitedIndia | 228 Pharma TradingImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13901-01 | May 15, 2028 | |
AmbiventSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg /500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Madecs Pharma CorporationImporter: I.E. Medica, Inc. | DRP-1419-10 | May 19, 2027 | |
AMBIVENTSalbutamol (as sulfate ) + Ipratropium bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL net content in 5 mL LDPE nebule (Box of 30 nebules in strips of 5's) | Rx | Amanta Healthcare LimitedIndia | MADECS PHARMA CORPORATIONImporter: I.E. Medica, Inc.Trader: MGRM Medicare Private Limited | DRP-4672-02 | Feb 2, 2028 | |
AmbiventSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5mg / 500mcg per 2.5ml Solution for Nebulization2.5ml LDPE Form-Fill Seal ampoule in Aluminum pouch (Box of 25's) | Rx | Legency Remedies Pvt. Ltd.India | Madecs Pharma CorporationImporter: Hillcross Prime Inc. | DRP-11062-06 | Jan 21, 2027 | |
AmsulduoSalbutamol (as sulafte) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution For Inhalation5 mL LDPE vial x 2.5 mL wrapped in aluminium foil in strips x 7's | Rx | Ahlcon Parenterals (India) LimitedIndia | Ambicare PharmaceuticalsImporter: Ambicare Pharmaceuticals, Inc.Trader: Highkon Pharma | DRP-13901 | May 15, 2028 | |
Asmagone PlusSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg / 500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | TGP Pharma Inc.Importer: I.E. Medica, Inc. | DRP-1419-09 | May 19, 2027 | |
Asmagone PlusSalbutamol (as Sulfate)+ Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL net content in 5 mL LDPE nebule (Box of 30 nebules in strips of 5's) | Rx | Amanta Healthcare LimitedIndia | TGP Pharma Inc.Importer: I.E. Medica Inc.Trader: MGRM Medicare Limited | DRP-4672-01 | Oct 29, 2028 | |
Aura 2Salbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill-Seal Ampoule in aluminum pouch (Box of 25's) | Rx | Legency Remedies Pvt. Ltd.India | All-Bio Pharma, Inc.Importer: Hillcross Prime, Inc. | DRP-11062-08 | Jan 21, 2027 | |
Aura PlusSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | All-Bio Pharma, Inc.Importer: I.E. Medica, Inc. | DRP-1419-11 | May 19, 2027 | |
Aura PlusSalbutamol (as sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL net content in 5 mL LDPE nebule (Box of 30 nebules in strips of 5's) | Rx | Amanta Healthcare LimitedIndia | All-Bio Pharma, Inc.Importer: I.E. Medica, Inc.Trader: MGRM Medicare Private Limited | DRP-4672-03 | Oct 29, 2028 | |
Bio-AireSalbutamol (as sulfate) + Ipratropium Bromide | 1 mg / 200 mcg per mL Solution for Inhalation2.5 mL polypropylene ampoule with protective cap (Box of 30's) | Rx | Ha Noi CPC1 Pharmaceutical Joint Stock CompanyVietnam | Bio Erixx Pharma DistributionImporter: AMB HK Enterprises Inc. | DRP-12785-03 | Oct 7, 2027 | |
BioventIpratropium Bromide + Salbutamol (as Sulfate) | 200 mcg/1 mg per mL Solution for Inhalation2.5mL Transluscent LDPE Ampoule (Box of 5's) | Rx | Geofman PharmaceuticalsPakistan | Amson PharmaceuticalsImporter: Sahar International Trading, Inc. | DRP-5276-01 | Jul 24, 2027 | |
BrevonebSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg / 500 mcg per 2.5 mL Solution For Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Ambicare Pharmaceuticals, Inc. | DRP-13048 | Nov 24, 2027 | |
Brodix PlusSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Medethix, Inc.Importer: I.E. Medica Inc. | DRP-1419-04 | May 19, 2027 | |
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL net content in 5 mL LDPE nebule Box of 30 nebules in strips of 5's | Rx | Amanta Healthcare Ltd.India | MedEthix Inc.Importer: I.E. Medica Inc.Trader: MGRM Medicare Pri vate Limited | DRP-4672-04 | Oct 29, 2028 | ||
BronchomideSalbutamol (as sulfate) + Ipratropium bromide | 1 mg/200 mcg per mL Solution for InhalationPolypropylene ampoule x 2.5 mL with protective cap (Box of 10’s, 25’s and 30’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Philrx Pharma Inc. | DRP-16273 | Jan 20, 2030 | |
BronchosalSalbutamol (As Salbutamol Sulfate) + Ipratropium Bromide | 1 mg/200 mcg per mL Solution for Inhalation2.5 mL polypropylene ampoule with protective cap (Box of 10's) | Rx | Ha Noi CPC1 Pharmaceutical Joint Stock CompanyVietnam | AMB HK Enterprises IncImporter: AMB HK Enterprises Inc. | DRP-12785 | Oct 7, 2027 | |
BronchoservSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill Seal Ampoule in Aluminum Pouch (Box of 25’s) | Rx | Legency Remedies Pvt. Ltd.India | Truserve Pharmaceutical DistributorImporter: Hillcross Prime Inc. | DRP-11062-03 | Jan 21, 2027 | |
Broncovent PlusIpratropium (as bromide) + Salbutamol (as sulfate) | 200 mcg / 1 mg per mL (500 mcg / 2.5 mg per 2.5 mL) Solution for Inhalation2.5 mL Polypropylene Ampoule x 5's in aluminum pouch (Box of 30's) and 7's in aluminum pouch (Box of 35's) | Rx | Althea Pharma Pvt. LtdIndia | Kaufmann Pharma Inc.Importer: Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10970-01 | Dec 29, 2026 | |
Broncovent PlusIpratropium bromide + Salbutamol (as sulfate) | 500 mcg/ 2.5 mg Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) | Rx | Legency Remedies Pvt. Ltd.India | Kaufmann Pharma Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-13475-03 | Feb 27, 2028 | |
Co-VentreeSalbutamol (as sulfate) + Ipratropium Bromide | 1 mg/200 mcg per mL Solution for Inhalation2.5 mL polypropylene ampoule with protective cap (Box of 10's) | Rx | Ha Noi CPC1 Pharmaceutical Joint Stock CompanyVietnam | PharmaTree Inc.Importer: AMB HK Enterprises Inc | DRP-12785-02 | Oct 7, 2027 | |
CombimistIpratropium Bromide + Salbutamol (as sulfate) | 500 mcg/2.5 mg Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) | Rx | Legency Remedies Pvt. Ltd.India | Zydus Healthcare Philippines Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-13475-01 | Feb 27, 2028 | |
CombipulSalbutamol (as sulfate) + Ipratropium (as bromide) | 1mg/200mcg per mL (2.5mg/500mcg per 2.5mL) Solution for InhalationLDPE plastic ampoule x 2.5mL (net content) in aluminum pouch x 5's (Box of 30's) | Rx | Legency Remedies Pvt. Ltd.India | Phil Pharmawealth, Inc.Importer: Endure Medical, Inc. | DRP-16038-01 | Oct 18, 2029 | |
CombipulIpratropium Bromide + Salbutamol (as Sulfate) | 20 mcg/100 mcg per Actuation Metered Dose Inhaler (CFC-Free)FCP Plasma Coated Aluminum Aerosol canister containing 200 metered doses + Polypropylene actuator (Box of 1's) Box of 1's | Rx | Cipla Ltd. (Unit I)India | Phil Pharmawealth, Inc. | DR-XY41122 | Oct 15, 2028 | |
CombipulIpratropium Bromide + Salbutamol (as Sulfate) | 500 mcg / 2.5 mg Solution for NebulizationLDPE nebule x 2.5 mL Box of 20's in Strips of 5 enclosed in an Aluminum Pouch | Rx | Cipla Ltd.India | Phil Pharmawealth, Inc. | DRP-6160 | Sep 8, 2030 | |
Combivent UDVIpratropium Bromide + Salbutamol (as Sulfate) | 500 mcg/ 2.5 mg/ 2.5 mL Solution for InhalationLDPE Vial x 2.5 mL (Box of 20's) | Rx | Laboratoire UnitherFrance | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-7891 | Feb 11, 2031 | |
DuaventIpratropium bromide (as monohydrate) + Salbutamol (as sulfate) | 500 mcg / 2.5 mg per 2.5 mL Solution for Nebulization2.5 mL LDPE blow-fill-seal ampoule x 5' in an aluminum/PE/PET laminated pouch (Box of 20's) | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DRP-16154 | Dec 22, 2026 | |
DuaventIpratropium bromide (as monohydrate) + Salbutamol (as sulfate) | 500 mcg/2.5 mg per 2.5 mL Solution For Nebulization2.5 mL LDPE blow-fill-seal ampoule x 5's in an aluminum/PE/PET laminated pouch (Box of 20's) | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY47628 | Dec 22, 2026 | |
DuodairSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation5 mL LDPE Vial in Aluminum Foil Pouch x 7's (Box of 7's and Box of 35’s) | Rx | Ahlcon Parenterals (India) LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-11882-02 | May 16, 2027 | |
DuolinSalbutamol (as sulfate) + Ipratropium Bromide | 100 mcg/20 mcg per Actuation Metered Dose Inhaler (CFC Free) (200 doses)Aluminum aerosol container containing 200 metered doses + polypropylene actuator (in a box) | Rx | Cipla Ltd. (Unit II)India | Healol Pharma Corporation | DR-XY46129 | Oct 25, 2027 | |
DuomedSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill Seal Ampoule in aluminum pouch (Box of 25’s) | Rx | Legency Remedies Pvt. Ltd.India | Medwise, Inc.Importer: Hillcross Prime Inc. | DRP-11062-02 | Jan 21, 2027 | |
Duorite RespulesSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill-Seal Ampoule in aluminum pouch (Box of 25's) | Rx | Legency Remedies Pvt. Ltd.India | Hillcross Prime Inc. | DRP-11062 | Jan 21, 2027 | |
DuosalbiumSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg / 500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Ambica International CorporationImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13048-04 | Nov 24, 2027 | |
DuosanSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill Seal Ampoule in aluminum pouch (Box of 25’s) | Rx | Legency Remedies Pvt. Ltd.India | Sanimed Pharmaceuticals Inc.Importer: Hillcross Prime Inc. | DRP-11062-01 | Jan 21, 2027 | |
DuoshangSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill Seal Ampoule in aluminum pouch (Box of 25's) | Rx | Legency Remedies Pvt. Ltd.India | Grabernoll Pharmaceutical CorporationImporter: Hillcross Prime, Inc. | DRP-11062-09 | Jan 21, 2027 | |
EmbuventSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Emhealthcare Pharma Traders Inc.Importer: I.E. Medica, Inc. | DRP-1419-14 | May 19, 2027 | |
Eurosalbu PlusIpratropium Bromide + Salbutamol (as sulfate) | 500 mcg / 2.5 mg Solution for InhalationLDPE Plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) | Rx | Legency Remedies Pvt. Ltd.India | Euro-Care Products PhilippinesImporter: Suhitas Pharmaceuticals Inc. | DRP-13475-02 | Feb 27, 2028 | |
GopraSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation5 mL LDPE Vial in Aluminum Foil Pouch x 7's (Box of 7's and Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc. | DRP-11882-03 | May 16, 2027 | |
Govent PlusIpratropium bromide + Salbutamol (as sulfate) | 500 mcg/2.5 mg per 2.5 mL Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 6 ampoules, Box of 30's) | Rx | Legency Remedies Pvt. LtdIndia | Applied Pharmaceutical Distribution IncImporter: Suhitas Pharmaceuticals Inc. | DRP-13475-09 | Feb 27, 2028 | |
Hivent PlusIpratropium Bromide + Salbutamol | 500 mcg/2.5 mg per 2.5 mL Solution for Inhalation2.5 mL LDPE Ampoule x 5 Ampoules per Foil Pouch (Box of 6 Foil Pouches) | Rx | Euro-Med Laboratories Phil., Inc.Philippines | — | DR-XY46417 | Sep 14, 2028 | |
I-Breath PlusSalbutamol (As Sulfate) + Ipratropium Bromide | 100mcg/20mcg Metered Dose InhalerAluminum canister fitted with metering valve x 200 metered doses (Box of 1's) | Rx | The ACME Laboratories Ltd.Bangladesh | Bell-Kenz Pharma, Inc.Importer: Euro Generics International Phils., Inc. | DR-XY45413 | Feb 28, 2028 | |
INHALIN IPRASalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg/500 mcg per 2.5 mL Nebulizer SolutionLDPE Nebule x 2.5 mL (Box of 20's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Aglobal Care, Inc. | DRP-17000 | Sep 4, 2030 | |
ipracareIpratropium Bromide + Salbutamol (as Sulfate) | 200 mcg/1mg per mL Solution for Inhalation2.5mL Translucent LDPE Ampoule (Box of 5's, 20's and 30's) | Rx | Geofman PharmaceuticalsPakistan | North Care Pharmaceutical DistributorshipImporter: Sahar International Trading, Inc. | DRP-5276-02 | Jul 24, 2027 | |
IpradenIpratropium Bromide + Salbutamol (as Sulfate) | 200 mcg/1 mg per mL Solution for Inhalation2.5mL Translucent LDPE Ampoule (5 Ampoule Enclosed in Aluminum Foil Pouch) (Box of 5's) | Rx | Geofman PharmaceuticalsPakistan | Cyden Medicale TradingImporter: Sahar International Trading, Inc. | DRP-5276-05 | Jul 24, 2027 | |
IpraferIpratropium Bromide + Salbutamol (as Sulfate) | 200 mcg/1 mg per mL Solution for inhalation2.5 mL Translucent LDPE Ampoule (5 Ampoules Enclosed in Aluminum Foil Pouch) (Box of 5's and 30's) | Rx | Geofman PharmaceuticalsPakistan | Ferma Drug EnterprisesImporter: Sahar International Trading Inc. | DRP-5276-06 | Jul 24, 2027 | |
IpralinIpratropium bromide + Salbutamol (as sulfate) | 20 mcg/100 mcg per actuation Suspension Metered Dose InhalerAluminum canister with metered valve and actuator x 200 actuations (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading Inc. | DR-XY45781 | Feb 14, 2027 | |
IpralinIpratropium bromide + Salbutamol (as sulfate) | 20 mcg/100 mcg per actuation Suspension Metered Dose InhalerAluminum canister with metered valve and actuator x 200 actuations (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading Inc. | DRP-12203 | Feb 14, 2027 | |
IpranebIpratropium Bromide + Salbutamol (as Sulfate) | 200 mcg/1mg per mL Solution for Inhalation2.5 mL Translucent LDPE Ampoule (Box of 5's) | Rx | Geofman PharmaceuticalsPakistan | Skymed Pharma DistributorImporter: Sahar International Trading Inc. | DRP-5276-03 | Jul 24, 2027 | |
IprasalSalbutamol (as sulfate) + Ipratropium bromide | 100 mcg/20 mcg Metered Dose Inhaler1 Aluminum Canister x 200 doses per box Not Applicable | Rx | Yangzhou No. 3 Pharmaceutical Co., LtdChina | Endure Medical Inc. | DR-XY44139 | Feb 9, 2031 | |
IprasalcareIpratropium Bromide + Salbutamol (As Sulfate) | 500 mcg/2.5 mg per 2.5 mL Solution for Inhalation Solution For Inhalation2.5 mL LDPE nebules x 10’s in aluminum pouch (Box of 10’s) | Rx | Joincare Haibin Pharmaceutical Co., Ltd.China | Joincare Pharma Philippines, Inc.Trader: N/A | DRP-14774 | Jun 15, 2031 | |
IpraventIpratropium Bromide + Salbutamol (as Sulfate) | 200 mcg/1 mg per mL Solution for Inhalation2.5mL Translucent LDPE Ampoule (5 Ampoules Enclosed in Aluminum Foil Pouch) (Box of 5's and 30's) | Rx | GEOFMAN PHARMACEUTICALSPakistan | SAHAR INTERNATIONAL TRADING INC. | DRP-5276 | Jul 24, 2027 | |
Iprax-MolSalbutamol(as sulfate) + Ipratropium Bromide | 2.5 mg + 500 mcg SOLUTION FOR INHALATION5 LDPE Respules x 2.5 mL packed in aluminium foil pouch (Box of 20's) | Rx | Axa Parenterals LimitedIndia | S.M.H.P. Marketing & Consultancy | DR-XY47648 | Jan 7, 2027 | |
Ipsa-DuoSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13048-05 | Nov 24, 2027 | |
LomatubsalSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg/ 500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Diafarm, Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13048-06 | Nov 24, 2027 | |
LupiventSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5mg/500mcg per 2.5mL Solution for Inhalation2.5mL LDPE Polyampoule x 7's Box of 21's and 35's | Rx | Ahlcon Parenterals (India) LimitedIndia | Importer: Lupin Philippines IncTrader: LUPIN LIMITED | DRP-4504 | Sep 4, 2027 | |
MultiventSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL LDPE Polyampoule x 7's (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Multicare Pharmaceuticals Phils. Inc.Importer: Lupin Philippines, Inc.Trader: Lupin Limited | DRP-4504-01 | Sep 4, 2027 | |
Multivent MDISalbutamol (as sulfate) + Ipratropium Bromide | 100 mcg / 20 mcg per Actuation Metered Dose InhalerAluminum Canister with pump actuator x 12g (Box of 1's) | Rx | Midas-Care Pharmaceuticals Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc.Importer: MedEthix, Inc. | DRP-4809-04 | Jun 28, 2027 | |
NebsadualSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Diafarm, Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13048-07 | Nov 24, 2027 | |
NebulentIpratropium bromide + Salbutamol (as sulfate) | 500 mcg/2.5 mg per 2.5 mL Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) | Rx | Legency Remedies Pvt. Ltd.India | Neo-Care PhilippinesImporter: Suhitas Pharmaceuticals Inc. | DRP-13475-05 | Feb 27, 2028 | |
NoneSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg / 500 mcg per 2.5 mL Solution for Inhalation5 mL LDPE Vial in Aluminum Foil Pouch x 7's (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Qualifirst Health Inc.Importer: Medinova Pharmaceutical Inc. | DRP-11882-04 | May 16, 2027 | |
noneSalbutamol (as sulfate) + Ipratropium bromide. | 2.5 mg/ 500 mcg per 2.5 mL Solution for NebulizationLDPE nebule x 5's in aluminum pouch (Box of 20's) | Rx | Cipla Limited (Unit I)India | SMHP Pharmaceuticals Incorporated. | DRP-14860 | Jan 25, 2029 | |
NoneSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL (net content) in 5 mL LDPE vial in Aluminum Foil Strip x 7’s (Box of 35’s) | Rx | Ahlcon Parenterals (India) LimitedIndia | Ambica International CorporationImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13048-01 | Nov 24, 2027 | |
NoneSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL Box of 35's | Rx | Ahlcon Parenterals (India) LimitedIndia | Madecs Pharma CorporationImporter: I.E. Medica, Inc. | DRP-1419-02 | May 19, 2027 | |
NoneSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Actimed, Inc.Importer: I.E. Medica, Inc. | DRP-1419-07 | May 19, 2027 | |
NoneSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc. | DRP-1419-12 | May 19, 2027 | |
NoneIpratropium (as bromide) + Salbutamol (as sulfate) | 200 mcg/ 1 mg per mL (500mcg/2.5 mg per 2.5 mL) Solution for Inhalation2.5 mL Polypropylene Ampoule x 5's in aluminum pouch (Box of 30's) and x 7's in aluminum pouch (Box of 35's) | Rx | Althea Pharma Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10970-02 | Dec 29, 2026 | |
Oranair PlusIpratropium Bromide + Salbutamol (as Sulfate) | 500 mcg/2.5 mg per 2.5 mL Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) | Rx | Legency Remedies Pvt. Ltd.India | Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-13475-04 | Feb 27, 2028 | |
Oustma PlusSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Plastic nebule x 2.5 mL (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc. | DRP-1419-05 | May 19, 2027 | |
PilltropiumSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7’s (Box of 35’s) | Rx | Ahlcon Parenterals (India) LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13048-08 | Nov 24, 2027 | |
PramolmaxSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill-Seal Ampoule in aluminum pouch (Box of 25's) | Rx | Legency Remedies Pvt. Ltd.India | Sefamax Pharmaceutical Products DistributionImporter: Hillcross Prime, Inc. | DRP-11062-05 | Jan 21, 2027 | |
PulmodualSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg / 500 mcg Solution for Inhalation5 LDPE Respules x 2.5 mL Packed in Aluminum Foil Pouch (Box of 20's) | Rx | Axa Parenterals LimitedIndia | The Cathay Drug Co., Inc.Importer: Preventia Healthcare Inc. | DRP-12113-01 | Jan 7, 2027 | |
PulmodualIpratropium (as bromide) + Salbutamol (as sulfate) | 500 mcg/2.5 mg per 2.5 mL Solution for Inhalation20 mL Ribbed Boston Round Amber Glass Bottle with Euro Dropper and Plastic Cap (Box of 1's) | Rx | EL Laboratories, Inc.Philippines | Trader: The Cathay Drug Co., Inc. | DR-XY35413 | Feb 9, 2029 | |
Pulmodual MDISalbutamol (as Sulfate) + Ipratropium Bromide | 100 mcg / 20 mcg per Actuation Metered Dose InhalerAluminum Canister with pump actuator x 12 g (Box of 1's) | Rx | Midas-Care Pharmaceuticals, Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: Medethix, Inc. | DRP-4809-03 | Jun 28, 2027 | |
Pulmodual MDISalbutamol (as sulfate) + Ipratropium Bromide | 100 mcg/20 mcg per Actuation Metered Dose InhalerAluminum Canister with Pump Actuator x 12 g (Box of 1's) | Rx | Midas-Care Pharmaceuticals Pvt. LtdIndia | The Cathay Drug Co., Inc.Importer: Medethix, Inc. | DRP-4809-02 | Jun 28, 2027 | |
Pulmodual MDISalbutamol (As Sulfate) + Ipratropium Bromide | 100mcg/20mcg Per Actuation Metered Dose InhalerAluminum Canister with pump actuator x 12 g (Box of 1's) | Rx | Midas-Care Pharmaceuticals Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: MedEthix, Inc. | DRP-4809 | Jun 28, 2027 | |
RelaxsaphIpratropium (as Bromide) + Salbutamol (as Sulfate) | 200 mcg/ 1 mg per mL (500 mcg/ 2.5 mg per 2.5 mL) Solution For Inhalation2.5 mL Polypropylene Ampoule x 5's in aluminum pouch (Box of 30's) and x 7's in aluminum pouch (Box of 35's) | OTC | Althea Pharma Pvt. Ltd.India | Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10970 | Dec 29, 2026 | |
Resease-IPSalbutamol (as sulfate) + Ipratropium bromide | 2.5mg/500mcg solution for Inhalation5 LDPE Respules x 2.5 mL Packed in Aluminum Foil Pouch (Box of 20's) | Rx | Axa Parenterals Ltd.India | Slanchi Pharma Inc.Importer: Preventia Healthcare Inc. | DRP-12113-02 | Jan 7, 2032 | |
Resposal-ISalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg / 500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc. | DRP-1419-13 | May 19, 2027 | |
Resposal-ISalbutamol (as sulfate) + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL net content in 5 mL LDPE nebule (Box of 30 nebules in strips of 5's) | Rx | Legency Remedies Pvt. Ltd.India | I.E. Medica Inc. | DRP-4672 | Feb 2, 2028 | |
Retavent PlusSalbutamol (as sulfate)+ Ipratropium (as bromide) | 2.5 mg / 500 mcg per 2.5 mL Solution for Inhalation5 mL LDPE Vial in Aluminum Foil Pouch x 7’s (Box of 7’s and 35’s) | Rx | Ahlcon Parenterals (India) LimitedIndia | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-11882-01 | May 16, 2027 | |
Retavent PlusSalbutamol (as sulfate) + Ipratropium bromide | 2.5mg/500 mcg per 2.5mL Nebulizer SolutionLDPE Nebule x 2.5mL (Box of 20"s) | Rx | Eurolife Healthcare Pvt. Ltd..India | Reta DrugImporter: Aglobal Care, Inc. | DRP-17000-01 | Sep 4, 2030 | |
Retavent PlusIpratropium bromide + Salbutamol (as sulfate) | 500 mcg / 2.5 mg Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) | Rx | Legency Remedies Pvt. Ltd.India | Reta DrugImporter: Suhitas Pharmaceuticals Inc. | DRP-13475-06 | Feb 27, 2028 | |
Retavent Plus RSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg / 500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Reta DrugImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13048-09 | Nov 24, 2027 | |
SalbipraSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg / 500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill-Seal Ampoule in aluminum pouch (Box of 25's) | Rx | Legency Remedies Pvt. Ltd.India | Euroasia Pharmaceuticals, Inc.Importer: Hillcross Prime, Inc. | DRP-11062-07 | Jan 21, 2027 | |
SalbipraSalbutamol (as sulfate) + Ipratropium bromide | 2.5mg/500mcg per 2.5mL Nebulizer SolutionLDPE Nebule x 2.5ml (Box of 20's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Euroasia Pharmaceuticals, IncImporter: AGlobal Care, Inc. | DRP-17000-02 | Sep 4, 2030 | |
SalbproduoSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg / 500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13048-10 | Nov 24, 2027 | |
SalbubamIpratropium bromide + Salbutamol (as sulfate) | 500 mcg/2.5 mg per 2.5 mL Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) | Rx | Legency Remedies Pvt. Ltd.India | Boon Pharma Corp.Importer: Suhitas Pharmaceuticals Inc. | DRP-13475-08 | Feb 27, 2028 | |
Salbucura PlusIpratropium bromide + Salbutamol (as sulfate) | 500 mcg/2.5 mg Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) (Box of 25’s) | Rx | Legency Remedies Pvt. Ltd.India | Rvm Pharma & Medical Supplies DistributionImporter: Suhitas Pharmaceuticals, Inc. | DRP-13475-10 | Feb 27, 2028 | |
Salbunov PlusSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation5 ml LDPE Vial in Aluminum Foil Pouch x 7's (Box of 7's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Medinova Pharmaceutical Inc. | DRP-11882 | May 16, 2027 | |
Salburex PlusSalbutamol (as Sulfate) + Ipratropium Bromide | 2.5 mg/ 500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill Seal Ampoule in aluminum pouch (Box of 25’s) | Rx | Legency Remedies Pvt. Ltd.India | Rexmed Pharmaceutical SalesImporter: Hillcross Prime Inc. | DRP-11062-04 | Jan 21, 2027 | |
SALMATE IpraSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg/500 mcg Solution for Inhalation5 LDPE Respules x 2.5 mL Packed in Aluminum Foil Pouch (Box of 20's) | Rx | Axa Parenterals LimitedIndia | Preventia Healthcare Inc. | DRP-12113 | Jan 7, 2032 | |
Salresp-ISalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's and Box of 30's); LDPE Nebule x 2.5 mL (Box of 35's )(with aluminum pouch) | Rx | Ahlcon Parenterals (India) LimitedIndia | I.E. Medica, Inc. | DRP-1419 | May 19, 2032 | |
SaltropiumSalbutamol (as sulfate) + Ipratropium bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL (net content) in 5 mL LDPE vial in Aluminum Foil Strip x 7’s (Box of 35’s) | Rx | Ahlcon Parenterals (India) LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-13048-02 | Nov 24, 2027 | |
SapiumIpratropium bromide + salbutamol (as sulfate) | 500 mcg/2.5 mg per 2.5 mL Solution For InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) | Rx | Legency Remedies Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-13475 | Feb 27, 2028 | |
Sethair DuoIpratropium bromide + Salbutamol (as sulfate) | 500 mcg/2.5 mg Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) | Rx | Legency Remedies Pvt. Ltd.India | 999 Seth Pharmaceutical Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-13475-07 | Feb 27, 2028 | |
UnbrandedSalbutamol (as sulfate) + Ipratropium (as bromide) | 2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Uniqure Pharma Inc.Importer: I.E. Medica, Inc. | DRP-1419-03 | May 19, 2027 | |
UnbrandedIpratropium bromide (as monohydrate) + Salbutamol (as sulfate) | 500 mcg / 2.5 mg per 2.5 mL Solution for Nebulization2.5 mL LDPE blow-fill-seal ampoule x 5's in an aluminum/PE/PET laminated pouch (Box of 20's) | Rx | Amherst Parenterals, Inc.Laguna | RiteMED Phils., Inc.Trader: UNILAB, Inc. | DRP-16154-01 | Dec 22, 2031 | |
UnbrandedIpratropium Bromide + Salbutamol (as Sulfate) | 500 mcg/2.5 mg/2.5 mL Solution for InhalationLDPE Vial x 2.5 mL (Box of 20's) | Rx | Laboratoire UnitherFrance | Philusa CorporationImporter: Boehringer Ingelheim (Philippines), Inc. | DRP-7891-01 | May 9, 2031 | |
VentulantSalbutamol Sulphate + Ipratropium Bromide | 2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL Low Density (LDPE) Ampoule x 5's in Aluminum pouch (Box of 30's) | Rx | Legency Remedies Pvt. Ltd.India | PhilRx Pharma, Inc. | DRP - 15355 | Jun 28, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS COMBIVENT RESPIMAT consists of a COMBIVENT RESPIMAT inhaler and an aluminum cylinder (COMBIVENT RESPIMAT cartridge) containing a combination of ipratropium bromide (monohydrate) and albuterol sulfate. The COMBIVENT RESPIMAT cartridge is only intended for use with the COMBIVENT RESPIMAT inhaler.
Each actuation from the COMBIVENT RESPIMAT inhaler delivers 20 mcg ipratropium bromide (monohydrate) and 100 mcg albuterol (equivalent to 120 mcg albuterol sulfate) from the mouthpiece. Inhalation spray: 20 mcg ipratropium bromide (monohydrate) and 100 mcg albuterol (equivalent to 120 mcg albuterol sulfate) per actuation with the COMBIVENT RESPIMAT inhaler (3)
Warnings/Precautions
- Paradoxical bronchospasm: Discontinue COMBIVENT RESPIMAT immediately and treat with alternative therapy if paradoxical bronchospasm occurs (5.1)
- Patients with cardiovascular system disorders: Use with caution because of beta-adrenergic stimulation (5.2)
- Ocular effects: Advise patients to avoid spraying into eyes and to contact a physician if blurred vision, halos, or other visual disturbances occur. Monitor patients with narrow-angle glaucoma. (5.3)
- Urinary retention: Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction (5.4)
- Hypersensitivity reactions including anaphylaxis: Discontinue COMBIVENT RESPIMAT and institute alternative therapy if immediate hypersensitivity reactions such as urticaria, angioedema, rash, bronchospasm, anaphylaxis, or oropharyngeal edema occur (5.6)
- Coexisting conditions: Use with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus (5.7)
5.1 Paradoxical Bronchospasm
5.1 Paradoxical Bronchospasm COMBIVENT RESPIMAT can produce paradoxical bronchospasm that can be life-threatening. If it occurs, therapy with COMBIVENT RESPIMAT should be discontinued immediately and alternative therapy instituted.
5.2 Cardiovascular Effects
5.2 Cardiovascular Effects The albuterol sulfate contained in COMBIVENT RESPIMAT, like other beta‑adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, and/or symptoms. If these symptoms occur, COMBIVENT RESPIMAT may need to be discontinued.
There is some evidence from postmarketing data and published literature of rare occurrences of myocardial ischemia associated with albuterol. In addition, beta‑adrenergic agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression.
Therefore, COMBIVENT RESPIMAT should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension [see Drug Interactions (7.2)].
5.3 Ocular Effects
5.3 Ocular Effects Ipratropium bromide, a component of COMBIVENT RESPIMAT, is an anticholinergic and may increase intraocular pressure. This may result in precipitation or worsening of narrow-angle glaucoma. Therefore, COMBIVENT RESPIMAT should be used with caution in patients with narrow-angle glaucoma [see Drug Interactions (7.1)].
Patients should avoid spraying COMBIVENT RESPIMAT into the eyes. If a patient sprays COMBIVENT RESPIMAT into their eyes they may cause acute eye pain or discomfort, temporary blurring of vision, mydriasis, visual halos, or colored images in association with red eyes from conjunctival or corneal congestion. Advise patients to consult their physician immediately if any of these symptoms develop while using COMBIVENT RESPIMAT.
5.4 Urinary Retention
5.4 Urinary Retention Ipratropium bromide, a component of COMBIVENT RESPIMAT, is an anticholinergic and may cause urinary retention. Therefore, caution is advised when administering this medication to patients with prostatic hyperplasia or bladder-neck obstruction [see Drug Interactions (7.1)].
5.5 Do Not Exceed Recommended Dosage
5.5 Do Not Exceed Recommended Dosage Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. The exact cause of death is unknown, but cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected [see Drug Interactions (7.2)].
5.6 Hypersensitivity Reactions Including Anaphylaxis
5.6 Hypersensitivity Reactions Including Anaphylaxis Hypersensitivity reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema may occur after administration of ipratropium bromide or albuterol sulfate. In clinical trials and postmarketing experience with ipratropium containing products, hypersensitivity reactions such as skin rash, pruritus, angioedema of tongue, lips and face, urticaria (including giant urticaria), laryngospasm, and anaphylactic reactions have been reported [see Adverse Reactions (6.1, 6.2)].
If such a reaction occurs, therapy with COMBIVENT RESPIMAT should be stopped at once and alternative treatment should be considered [see Contraindications (4)].
5.7 Coexisting Conditions
5.7 Coexisting Conditions COMBIVENT RESPIMAT contains albuterol sulfate, a beta 2 -adrenergic sympathomimetic amine and, therefore, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus, and in patients who are unusually responsive to sympathomimetic amines.
5.8 Hypokalemia Beta 2
5.8 Hypokalemia Beta 2 ‑adrenergic agonists may produce significant hypokalemia in some patients (possibly through intracellular shunting) which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation [see Drug Interactions (7.2)].
Drug interactions
- COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.1)
- Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7.2)
- Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7.3)
- Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of beta-agonists. Consider monitoring potassium levels. (7.4)
- Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants: May potentiate effect of albuterol on the vascular system. Consider alternative therapy in patients taking MAOs or tricyclic antidepressants. (7.5)
7.1 Anticholinergic Agents
7.1 Anticholinergic Agents There is the potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see Warnings and Precautions (5.3, 5.4)].
7.2 Beta
7.2 Beta‑adrenergic Agonists Caution is advised in the coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents due to the increased risk of adverse cardiovascular effects [see Warnings and Precautions (5.2, 5.5)].
7.3 Beta-receptor Blocking Agents
7.3 Beta-receptor Blocking Agents Beta-receptor blocking agents and albuterol inhibit the effect of each other. Beta-receptor blocking agents should be used with caution in patients with hyperreactive airways.
7.4 Diuretics The
7.4 Diuretics The ECG changes and/or hypokalemia which may result from the administration of non‑potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta 2 -agonists, especially when the recommended dosage of the beta 2 -agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonist‑containing drugs, such as COMBIVENT RESPIMAT, with non‑potassium sparing diuretics.
Consider monitoring potassium levels.
7.5 Monoamine Oxidase Inhibitors or Tricyclic Antidepressants
7.5 Monoamine Oxidase Inhibitors or Tricyclic Antidepressants COMBIVENT RESPIMAT should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants or within 2 weeks of discontinuation of such agents because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy in patients taking MAOs or tricyclic antidepressants [see Warnings and Precautions (5.2)].
Adverse reactions
- Use of albuterol, a beta 2 -adrenergic agonist, may be associated with the following: Paradoxical bronchospasm [see Warnings and Precautions (5.1)] Cardiovascular effects [see Warnings and Precautions (5.2)] Hypersensitivity reactions including anaphylaxis [see Contraindications (4) and Warnings and Precautions (5.6)] Hypokalemia [see Warnings and Precautions (5.8)] Albuterol is a component of COMBIVENT RESPIMAT. Use of ipratropium bromide, an anticholinergic, may result in the following: Ocular effects [see Warnings and Precautions (5.3)] Urinary retention [see Warnings and Precautions (5.4)] Ipratropium bromide is a component of COMBIVENT RESPIMAT. Most common (≥2%) adverse reactions for COMBIVENT RESPIMAT (20/100 mcg) are upper respiratory infection, nasopharyngitis, cough, bronchitis, headache, and dyspnea (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience COMBIVENT RESPIMAT 12-Week Clinical Trials The safety data described in Table 1 below are derived from one 12-week, randomized, multicenter, double-blind, double-dummy, parallel-group trial that compared COMBIVENT RESPIMAT (20/100 mcg), CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg), and ipratropium bromide delivered by the RESPIMAT inhaler (20 mcg) administered four times a day in 1,460 adult COPD patients (955 males and 505 females) 40 years of age and older. Of these patients, 486 were treated with COMBIVENT RESPIMAT.
The COMBIVENT RESPIMAT group was composed of mostly Caucasian (88.5%) patients with a mean age of 63.8 years, and a mean percent predicted FEV 1 at screening of 41.5%. Patients with narrow-angle glaucoma, symptomatic prostatic hypertrophy or bladder-neck obstruction were excluded from the trial. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Table 1 shows all adverse reactions that occurred with a frequency of ≥2% in the COMBIVENT RESPIMAT treatment group in the 12-week COPD trial. The frequency of the corresponding adverse reactions in the CFC-propelled COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the RESPIMAT inhaler groups is included for comparison.
The rates are derived from all reported adverse reactions of that type not present at baseline, whether considered drug-related or not by the clinical investigator. Table 1 Adverse Reactions in ≥2% of Patients in the COMBIVENT RESPIMAT Group in a 12-Week COPD Clinical Trial Body System (Event) 12-Week Ipratropium-Controlled Trial COMBIVENT RESPIMAT (20/100 mcg) CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg) Ipratropium bromide by the RESPIMAT Inhaler (20 mcg) [n=486] [n=491] [n=483] Patients with any adverse reaction 46 52 45 Respiratory, thoracic, and mediastinal disorders Cough Dyspnea 3 2 2 2 2 3 Nervous system disorders Headache 3 2 3 Infections and infestations Bronchitis Nasopharyngitis Upper Respiratory infection 3 4 3 3 3 4 1 4 3 Adverse reactions that occurred in <2% in the COMBIVENT RESPIMAT (20/100 mcg) group observed in this 12-week trial include: Vascular disorders: hypertension; Nervous system disorders: dizziness and tremor; Musculoskeletal and connective tissue disorder: muscle spasms and myalgia; Gastrointestinal disorders: diarrhea, nausea, dry mouth, constipation, and vomiting; General disorders and administration site conditions: asthenia, influenza-like illness, and chest discomfort; Eye disorders: eye pain; Metabolism and nutritional disorders: hypokalemia; Cardiac disorders: palpitations and tachycardia; Skin and subcutaneous tissue disorders: pruritus and rash; Respiratory, thoracic, and mediastinal disorders; pharyngolaryngeal pain and wheezing.
A separate 12-week trial evaluated a higher than approved dosage of COMBIVENT RESPIMAT in 1,118 COPD patients. Patients were randomized to COMBIVENT RESPIMAT (40/200 mcg) (n=345), CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg) (n=180), ipratropium delivered by the RESPIMAT (40 mcg) (n=252) or placebo (n=341). The overall incidence and nature of adverse reactions observed were similar to the adverse reactions seen with COMBIVENT RESPIMAT 20/100 mcg.
COMBIVENT RESPIMAT Long-Term (48-week) Safety Trial Long-term chronic use safety data for COMBIVENT RESPIMAT were obtained from one 48-week, randomized, multicenter, open-label, parallel-group trial that compared COMBIVENT RESPIMAT (20/100 mcg), CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg), and the free combination of ipratropium bromide (34 mcg) and albuterol (180 mcg) HFA inhalation aerosols administered 4 times a day in 465 adult COPD patients (273 males and 192 females) 40 years of age and older. Of these patients, 157 were treated with COMBIVENT RESPIMAT.
The COMBIVENT RESPIMAT group was composed of mostly Caucasian (93.5%) patients with a mean age of 62.9 years, and a mean percent predicted FEV 1 at screening of 47.0%. An evaluation of the safety data from the trial revealed that most adverse reactions were similar in type and rate between treatment groups. However, cough occurred more frequently in patients enrolled in the COMBIVENT RESPIMAT group (7.0%) compared to those in the CFC-propelled COMBIVENT Inhalation Aerosol (2.6%) or the free combination of ipratropium bromide and albuterol HFA inhalation aerosols (3.9%) groups.
In addition to the adverse reactions reported in the controlled clinical trial with COMBIVENT RESPIMAT, adverse reaction information concerning CFC-propelled COMBIVENT Inhalation Aerosol is derived from two 12-week controlled clinical trials (N=358 for CFC-propelled COMBIVENT Inhalation Aerosol). Adverse reactions reported in ≥2% of patients in the CFC-propelled COMBIVENT Inhalation Aerosol treatment group include: bronchitis, upper respiratory tract infection, headache, dyspnea, cough, pain, respiratory disorder, sinusitis, pharyngitis, and nausea.
Adverse reactions reported in <2% of patients in the CFC-propelled COMBIVENT Inhalation Aerosol treatment group include: edema, fatigue, hypertension, dizziness, nervousness, tremor, dysphonia, insomnia, diarrhea, dry mouth, dyspepsia, vomiting, arrhythmia, palpitation, tachycardia, arthralgia, angina, increased sputum, taste perversion, urinary tract infection, dysuria, dry throat, and bronchospasm.
6.2 Postmarketing Experience
6.2 Postmarketing Experience In addition to the adverse reactions reported during clinical trials, the following adverse reactions have been identified during post-approval use of CFC-propelled COMBIVENT Inhalation Aerosol. Since CFC-propelled COMBIVENT Inhalation Aerosol and COMBIVENT RESPIMAT contain the same active ingredients, one should take into account the fact that the adverse reactions seen with CFC-propelled COMBIVENT Inhalation Aerosol could also occur with COMBIVENT RESPIMAT.
Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Eye disorders: glaucoma, blurred vision, mydriasis, conjunctival hyperemia, halo vision, accommodation disorder, ocular irritation, and corneal edema Gastrointestinal disorders: gastrointestinal motility disorder, drying of secretions, stomatitis, and mouth edema Immune system disorders: hypersensitivity Investigations: intraocular pressure increased, blood pressure diastolic decreased, and blood pressure systolic increased Musculoskeletal and connective tissue disorders: muscular weakness Psychiatric disorders: CNS stimulation, mental disorder Respiratory, thoracic, and mediastinal disorders: throat irritation, paradoxical bronchospasm, wheezing, nasal congestion, and pharyngeal edema Skin and subcutaneous tissue disorders: angioedema, hyperhidrosis, and skin reaction Urinary disorders: urinary retention Cardiac disorders: myocardial ischemia Allergic-type reactions such as skin reactions including rash, pruritus, and urticaria (including giant urticaria), angioedema including that of tongue, lips and face, laryngospasm, and anaphylactic reaction have also been reported with CFC-propelled COMBIVENT Inhalation Aerosol, with positive re-challenge in some cases [see Warnings and Precautions (5.6)].
In a 5-year placebo-controlled trial, hospitalizations for supraventricular tachycardia and/or atrial fibrillation occurred with an incidence rate of 0.5% in COPD patients receiving CFC-propelled ATROVENT® (ipratropium bromide) Inhalation Aerosol. Metabolic acidosis has been reported with use of albuterol-containing products.
Adverse reaction frequency tables (US label) US FDA label
| Body System (Event) | 12-Week Ipratropium-Controlled Trial | |||
| COMBIVENT RESPIMAT (20/100 mcg) | CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg) | Ipratropium bromide by the RESPIMAT Inhaler (20 mcg) | ||
| [n=486] | [n=491] | [n=483] | ||
| Patients with any adverse reaction | 46 | 52 | 45 | |
| Respiratory, thoracic, and mediastinal disorders | ||||
| Cough Dyspnea | 3 2 | 2 2 | 2 3 | |
| Nervous system disorders | ||||
| Headache | 3 | 2 | 3 | |
| Infections and infestations | ||||
| Bronchitis Nasopharyngitis Upper Respiratory infection | 3 4 3 | 3 3 4 | 1 4 3 | |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no randomized clinical studies of COMBIVENT RESPIMAT, or its individual components, ipratropium bromide and albuterol sulfate, in pregnant women. Ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see Clinical Pharmacology (12.3)].
Published literature, including cohort studies, case control studies and case series, over several decades have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes with ipratropium bromide. Available data from published epidemiological studies and postmarketing case reports of pregnancy outcomes following inhaled albuterol use do not consistently demonstrate a risk of major birth defects or, miscarriage.
There are clinical considerations with the use of COMBIVENT RESPIMAT in pregnant women [see Clinical Considerations]. Animal reproduction studies have not been conducted with COMBIVENT RESPIMAT, however, animal studies are available with its individual components, ipratropium bromide and albuterol sulfate. Based on oral reproduction studies, no evidence of structural alterations was observed when ipratropium bromide was administered to pregnant mice, rats, and rabbits during organogenesis at doses approximately 340, 68,000 and 17,000 times, respectively, the maximum recommended human daily inhalation dose (MRHDID) in adults on a mg/m 2 basis.
When albuterol was administered to pregnant mice during organogenesis there was evidence of cleft palate at doses approximately equivalent to the maximum recommended human daily inhalation dose (MRHDID) [see Data]. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Consideration Labor or Delivery Because of the potential for beta-agonist interference with uterine contractility, use of COMBIVENT RESPIMAT for the treatment of COPD during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.
Serious adverse reactions, including pulmonary edema, have been reported during or following treatment of premature labor with beta 2 -agonists, including albuterol. Data Animal Data Ipratropium bromide In animal reproduction studies, oral and inhalation administration of ipratropium bromide to pregnant mice, rats and rabbits during the period of organogenesis did not show evidence of fetal structural alterations.
The ipratropium dose in oral studies in mice, rats, and rabbits was up to approximately 340, 68,000 and 17,000 times, respectively, the maximum recommended human daily inhalation dose (MRHDID) in adults (on a mg/m 2 basis at maternal doses in each species of 10, 1,000 and 125 mg/kg/day, respectively). The ipratropium dose in inhalation studies in rats and rabbits was up to approximately 100 and 240 times, respectively, the MRHDID in adults (on a mg/m 2 basis at maternal doses of 1.5 and 1.8 mg/kg/day, respectively).
Embryotoxicity was observed as increased resorption in rats at oral doses approximately 6,100 times MRHDID in adults (on a mg/m 2 basis at maternal doses of 90 mg/kg/day and above). This effect is not considered relevant to human use due to the large doses at which it was observed and the difference in route of administration.
Albuterol In a mouse reproduction study, subcutaneously administered albuterol sulfate produced cleft palate formation in 5 of 111 (4.5%) fetuses at a dose approximately equivalent to the MRHDID in adults (on a mg/m 2 basis at a maternal dose of 0.25 mg/kg/day) and in 10 of 108 (9.3%) fetuses at approximately 14 times the MRHDID in adults (on a mg/m 2 basis at a maternal dose of 2.5 mg/kg/day). Similar effects were not observed at approximately less than MRHDID in adults (on a mg/m 2 basis at a maternal dose of 0.025 mg/kg/day).
Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated with 2.5 mg/kg/day isoproterenol (positive control). In a rabbit reproductive study, orally administered albuterol sulfate induced cranioschisis in 7 of 19 (37%) fetuses at approximately 1,100 times the MRHDID in adults (on a mg/m 2 basis at a maternal dose of 50 mg/kg/day).
In a rat reproduction study, an albuterol sulfate/HFA-134a formulation administered by inhalation did not produce any teratogenic effects at exposures approximately 80 times the MRHDID (on a mg/m 2 basis at a maternal dose of 10.5 mg/kg). A study in which pregnant rats were dosed with radiolabeled albuterol sulfate demonstrated that drug-related material is transferred from the maternal circulation to the fetus.
Mechanism of action
12.1 Mechanism of Action COMBIVENT RESPIMAT: COMBIVENT RESPIMAT is a combination of the anticholinergic ipratropium bromide and the beta 2 -adrenergic agonist albuterol sulfate. The mechanisms of action described below for the individual components apply to COMBIVENT RESPIMAT. The two classes of medications (an anticholinergic and a beta 2 -adrenergic agonist) are both bronchodilators.
Simultaneous administration of both an anticholinergic (ipratropium bromide) and a beta 2 -sympathomimetic (albuterol sulfate) is designed to produce a greater bronchodilator effect than when either drug is utilized alone at its recommended dosage. The efficacy of COMBIVENT RESPIMAT is likely to be due to a local effect on the muscarinic and beta 2 -adrenergic receptors in the lung.
Ipratropium bromide Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.
Albuterol sulfate In vitro studies and in vivo pharmacology studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors on bronchial smooth muscle, recent data indicate that there is a population of beta 2 -receptors in the human heart which comprise between 10% and 50% of cardiac beta-adrenergic receptors.
The precise function of these receptors, however, is not yet established [see Warnings and Precautions (5.2)]. Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylyl cyclase and to an increase in the intracellular concentration of cyclic-3',5'-adenosine monophosphate (cyclic AMP).
This increase of cyclic AMP leads to the activation of protein kinase, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. Albuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Albuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges.
Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway. Albuterol has been shown in most clinical trials to have more bronchial smooth muscle relaxation effect than isoproterenol at comparable doses while producing fewer cardiovascular effects. However, all beta‑adrenergic agonist drugs, including albuterol sulfate, can produce a significant cardiovascular effect in some patients [see Warnings and Precautions (5.2)].
Ipratropium bromide Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.
Albuterol sulfate In vitro studies and in vivo pharmacology studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors on bronchial smooth muscle, recent data indicate that there is a population of beta 2 -receptors in the human heart which comprise between 10% and 50% of cardiac beta-adrenergic receptors.
The precise function of these receptors, however, is not yet established [see Warnings and Precautions (5.2)]. Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylyl cyclase and to an increase in the intracellular concentration of cyclic-3',5'-adenosine monophosphate (cyclic AMP).
This increase of cyclic AMP leads to the activation of protein kinase, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. Albuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Albuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges.
Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway. Albuterol has been shown in most clinical trials to have more bronchial smooth muscle relaxation effect than isoproterenol at comparable doses while producing fewer cardiovascular effects. However, all beta‑adrenergic agonist drugs, including albuterol sulfate, can produce a significant cardiovascular effect in some patients [see Warnings and Precautions (5.2)].
Ipratropium bromide Cardiovascular effects At recommended dosages, ipratropium bromide does not produce clinically significant changes in pulse rate or blood pressure. Ocular effects In studies without a positive control, ipratropium bromide did not alter pupil size, accommodation, or visual acuity. Mucociliary clearance and respiratory secretions Controlled clinical studies have demonstrated that ipratropium bromide does not alter either mucociliary clearance or the volume or viscosity of respiratory secretions.
Albuterol sulfate Cardiovascular effects Controlled clinical trials and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.
Ipratropium bromide Ipratropium bromide is a quaternary amine and hence, it is not readily absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract as confirmed by blood level and renal excretion studies. The half-life of elimination is about 2 hours after inhalation or intravenous administration.
Ipratropium bromide is minimally bound (0% to 9% in vitro) to plasma albumin and α 1 -acid glycoprotein. It is partially metabolized to inactive ester hydrolysis products. Following intravenous administration, approximately one-half of the dose is excreted unchanged in the urine.
Albuterol sulfate Albuterol is longer acting than isoproterenol in most patients because it is not a substrate for the cellular uptake processes for catecholamines, nor for metabolism by catechol-O-methyl transferase. Instead, the drug is conjugatively metabolized to albuterol 4'-O-sulfate. Intravenous pharmacokinetics of albuterol was studied in a comparable group of 16 healthy male volunteers; the mean terminal half-life following a 30-minute infusion of 1.5 mg was 3.9 hours, with a mean clearance of 439 mL/min/1.73 m².
COMBIVENT RESPIMAT Inhalation Spray In a 12-week randomized, multicenter, double-blind, double-dummy parallel group trial, 108 US patients with COPD receiving either COMBIVENT RESPIMAT (20/100 mcg) or CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg) four times daily participated in pharmacokinetic evaluations. Plasma ipratropium concentrations were low with an average peak plasma concentration of 33.5 pg/mL from COMBIVENT RESPIMAT.
The majority of the study participants exhibited levels below the lower limit of quantitation (<10 pg/mL) by 4 to 6 hours following dosing. The steady state systemic exposure obtained for ipratropium bromide following COMBIVENT RESPIMAT was comparable to that of CFC-propelled COMBIVENT Inhalation Aerosol. Ipratropium plasma AUC and total amount of drug excreted unchanged in urine (Ae) ratios for COMBIVENT RESPIMAT/CFC-propelled COMBIVENT Inhalation Aerosol were 1.04 and 1.18, respectively.
For albuterol the steady state systemic exposure was less from COMBIVENT RESPIMAT compared to that of CFC-propelled COMBIVENT Inhalation Aerosol. Albuterol plasma AUC and urine Ae ratios for COMBIVENT RESPIMAT/CFC-propelled COMBIVENT Inhalation Aerosol were 0.74 and 0.86, respectively. Pharmacokinetic drug-drug interaction between ipratropium bromide and albuterol sulfate was evaluated in a crossover study in 12 healthy male volunteers who received CFC-propelled COMBIVENT Inhalation Aerosol and the two active components separately as individual treatments.
Results from this study indicated that the coadministration of these two components from a single canister did not significantly alter the systemic absorption of either component, indicating lack of any pharmacokinetic interaction between these two drugs.
Specific Populations Age Consistent with CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg), patients receiving COMBIVENT RESPIMAT (20/100 mcg) aged 65 years and over had higher steady state systemic exposures than patients aged under 65 years for both ipratropium (AUC = 166 vs. 105 pg•hr/mL, C max = 38.5 vs. 30.1 pg/mL) and albuterol (AUC = 5.44 vs. 3.27 ng•hr/mL, C max = 1.19 vs. 0.74 ng/mL). Gender The AUC and C max values for ipratropium were 131 pg.hr/mL and 35.4 pg/mL in males and 123 pg.hr/mL and 31.7 pg/mL in females, respectively.
The AUC- and C max -values for albuterol were 4.0 ng•hr/mL and 0.89 ng/mL in males and 4.2 ng•hr/mL and 0.93 ng/mL in females, respectively. Hepatic and Renal Impairment The pharmacokinetics of COMBIVENT RESPIMAT or ipratropium bromide has not been studied in patients with hepatic or renal insufficiency. Drug-Drug Interactions No specific pharmacokinetic studies were conducted to evaluate potential drug-drug interactions with other medications.
Ipratropium bromide Two-year oral carcinogenicity studies in rats and mice have revealed no carcinogenic activity at doses up to 6 mg/kg/day (approximately 400 and 200 times the maximum recommended human daily inhalation dose of ipratropium bromide (MRHDID) in adults on a mg/m 2 basis, respectively). Results of various mutagenicity/clastogenicity studies (Ames test, mouse dominant lethal test, mouse micronucleus test, and chromosome aberration of bone marrow in Chinese hamsters) were negative.
Fertility of male or female rats at oral doses up to 50 mg/kg/day (approximately 3,400 times the MRHDID in adults on a mg/m 2 basis) was unaffected by ipratropium bromide administration. At an oral dose of 500 mg/kg/day (approximately 34,000 times the MRHDID in adults on a mg/m 2 basis), ipratropium bromide produced a decrease in the conception rate.
Albuterol Like other agents in its class, albuterol caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium in a 2-year study in the rat at dietary doses of 2, 10, and 50 mg/kg/day (approximately 20, 110, and 560 times the MRHDID on a mg/m 2 basis). In another study this effect was blocked by the coadministration of propranolol.
The relevance of these findings to humans is not known. An 18-month study in mice at dietary doses up to 500 mg/kg/day (approximately 2,800 times the MRHDID on a mg/m 2 basis) and a 99-week study in hamsters at oral doses up to 50 mg/kg/day (approximately 470 times the MRHDID on a mg/m 2 basis) revealed no evidence of tumorigenicity.
Studies with albuterol revealed no evidence of mutagenesis. Reproduction studies in rats with albuterol sulfate revealed no evidence of impaired fertility.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Ipratropium bromide Cardiovascular effects At recommended dosages, ipratropium bromide does not produce clinically significant changes in pulse rate or blood pressure. Ocular effects In studies without a positive control, ipratropium bromide did not alter pupil size, accommodation, or visual acuity.
Mucociliary clearance and respiratory secretions Controlled clinical studies have demonstrated that ipratropium bromide does not alter either mucociliary clearance or the volume or viscosity of respiratory secretions. Albuterol sulfate Cardiovascular effects Controlled clinical trials and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.
Pharmacokinetics
12.3 Pharmacokinetics Ipratropium bromide Ipratropium bromide is a quaternary amine and hence, it is not readily absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract as confirmed by blood level and renal excretion studies.
The half-life of elimination is about 2 hours after inhalation or intravenous administration.
Following intravenous administration, approximately one-half of the dose is excreted unchanged in the urine.
Intravenous pharmacokinetics of albuterol was studied in a comparable group of 16 healthy male volunteers; the mean terminal half-life following a 30-minute infusion of 1.5 mg was 3.9 hours, with a mean clearance of 439 mL/min/1.73 m 2 .
Ipratropium plasma AUC and total amount of drug excreted unchanged in urine (Ae) ratios for COMBIVENT RESPIMAT/CFC-propelled COMBIVENT Inhalation Aerosol were 1.04 and 1.18, respectively.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Ipratropium bromide Ipratropium bromide is a quaternary amine and hence, it is not readily absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract as confirmed by blood level and renal excretion studies. The half-life of elimination is about 2 hours after inhalation or intravenous administration.
Ipratropium bromide is minimally bound (0% to 9% in vitro) to plasma albumin and α 1 -acid glycoprotein. It is partially metabolized to inactive ester hydrolysis products. Following intravenous administration, approximately one-half of the dose is excreted unchanged in the urine. Albuterol sulfate Albuterol is longer acting than isoproterenol in most patients because it is not a substrate for the cellular uptake processes for catecholamines, nor for metabolism by catechol-O-methyl transferase.
Instead, the drug is conjugatively metabolized to albuterol 4'-O-sulfate. Intravenous pharmacokinetics of albuterol was studied in a comparable group of 16 healthy male volunteers; the mean terminal half-life following a 30-minute infusion of 1.5 mg was 3.9 hours, with a mean clearance of 439 mL/min/1.73 m². COMBIVENT RESPIMAT Inhalation Spray In a 12-week randomized, multicenter, double-blind, double-dummy parallel group trial, 108 US patients with COPD receiving either COMBIVENT RESPIMAT (20/100 mcg) or CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg) four times daily participated in pharmacokinetic evaluations.
Plasma ipratropium concentrations were low with an average peak plasma concentration of 33.5 pg/mL from COMBIVENT RESPIMAT. The majority of the study participants exhibited levels below the lower limit of quantitation (<10 pg/mL) by 4 to 6 hours following dosing. The steady state systemic exposure obtained for ipratropium bromide following COMBIVENT RESPIMAT was comparable to that of CFC-propelled COMBIVENT Inhalation Aerosol.
Ipratropium plasma AUC and total amount of drug excreted unchanged in urine (Ae) ratios for COMBIVENT RESPIMAT/CFC-propelled COMBIVENT Inhalation Aerosol were 1.04 and 1.18, respectively. For albuterol the steady state systemic exposure was less from COMBIVENT RESPIMAT compared to that of CFC-propelled COMBIVENT Inhalation Aerosol.
Albuterol plasma AUC and urine Ae ratios for COMBIVENT RESPIMAT/CFC-propelled COMBIVENT Inhalation Aerosol were 0.74 and 0.86, respectively. Pharmacokinetic drug-drug interaction between ipratropium bromide and albuterol sulfate was evaluated in a crossover study in 12 healthy male volunteers who received CFC-propelled COMBIVENT Inhalation Aerosol and the two active components separately as individual treatments.
Results from this study indicated that the coadministration of these two components from a single canister did not significantly alter the systemic absorption of either component, indicating lack of any pharmacokinetic interaction between these two drugs. Specific Populations Age Consistent with CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg), patients receiving COMBIVENT RESPIMAT (20/100 mcg) aged 65 years and over had higher steady state systemic exposures than patients aged under 65 years for both ipratropium (AUC = 166 vs. 105 pg•hr/mL, C max = 38.5 vs. 30.1 pg/mL) and albuterol (AUC = 5.44 vs. 3.27 ng•hr/mL, C max = 1.19 vs. 0.74 ng/mL).
Gender The AUC and C max values for ipratropium were 131 pg.hr/mL and 35.4 pg/mL in males and 123 pg.hr/mL and 31.7 pg/mL in females, respectively. The AUC- and C max -values for albuterol were 4.0 ng•hr/mL and 0.89 ng/mL in males and 4.2 ng•hr/mL and 0.93 ng/mL in females, respectively. Hepatic and Renal Impairment The pharmacokinetics of COMBIVENT RESPIMAT or ipratropium bromide has not been studied in patients with hepatic or renal insufficiency.
Drug-Drug Interactions No specific pharmacokinetic studies were conducted to evaluate potential drug-drug interactions with other medications.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Ipratropium + Salbutamol 500 mcg + 2.5 mg x 2.5 mL (unit dose) Respiratory Solution | ₱7.00–₱24.41Reference ₱9.65 | per unit | DPRI procurement range |
| 20 mcg (as bromide) + 100 mcg x 200 doses x 10 mL MDI | ₱1,083.00 | per unit | PhilHealth GAMOT fixed fee |
| 500 mcg (as bromide anhydrous) + 2.5 mg (as base) respiratory solution in 2.5 mL unit dose (for nebulization) | ₱45.25 | per unit | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Ipratropium + Salbutamol |
| PNF listing | MDI: 20 micrograms ipratropium (as bromide) + 100 micrograms salbutamol x 200 doses x 10mL |
| PNF listing | Resp. Soln.: (for nebulization) |
| PNF listing | Resp. Soln.: 500 micrograms ipratropium (as bromide anhydrous) + 2.5 mg salbutamol (as base) x |
| PNF listing | Resp. Soln.: 2.5 mL (unit dose) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Combivent Respimat · Boehringer Ingelheim Pharmaceuticals, Inc. [US FDA-approved label, version 18, December 1, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9832312e-0310-4ab6-8501-afa976fc7eb2
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .